S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:PRTO

Proteon Therapeutics Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
$13.75
-2.30 (-14.33 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.51
Now: $13.75
$16.01
50-Day Range
$0.84
MA: $19.37
$25.13
52-Week Range
$0.22
Now: $13.75
$3.94
Volume217,394 shs
Average Volume1.11 million shs
Market Capitalization$304.96 million
P/E RatioN/A
Dividend YieldN/A
Beta0.6

Competitors

Proteon Therapeutics (NASDAQ:PRTO) Vs. PCVX, CHRS, MESO, CRTX, ADVM, and INBX

Should you be buying PRTO stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Proteon Therapeutics, including Vaxcyte (PCVX), Coherus BioSciences (CHRS), Mesoblast (MESO), Cortexyme (CRTX), Adverum Biotechnologies (ADVM), and Inhibrx (INBX).

Proteon Therapeutics (NASDAQ:PRTO) and Vaxcyte (NASDAQ:PCVX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Proteon Therapeutics and Vaxcyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Proteon TherapeuticsN/AN/A-118.68%
VaxcyteN/AN/AN/A

Insider and Institutional Ownership

23.0% of Proteon Therapeutics shares are owned by institutional investors. Comparatively, 74.1% of Vaxcyte shares are owned by institutional investors. 45.7% of Proteon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Proteon Therapeutics and Vaxcyte's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteon TherapeuticsN/AN/A$-20,730,000.00($1.15)-11.96
VaxcyteN/AN/A$-50,270,000.00N/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Proteon Therapeutics and Vaxcyte, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Proteon Therapeutics0000N/A
Vaxcyte00403.00

Vaxcyte has a consensus target price of $48.00, indicating a potential upside of 103.22%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Proteon Therapeutics.

Summary

Vaxcyte beats Proteon Therapeutics on 4 of the 6 factors compared between the two stocks.

Proteon Therapeutics (NASDAQ:PRTO) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Volatility & Risk

Proteon Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Valuation and Earnings

This table compares Proteon Therapeutics and Coherus BioSciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteon TherapeuticsN/AN/A$-20,730,000.00($1.15)-11.96
Coherus BioSciences$356.07 million3.12$89.83 million$1.2312.39

Coherus BioSciences has higher revenue and earnings than Proteon Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

23.0% of Proteon Therapeutics shares are held by institutional investors. 45.7% of Proteon Therapeutics shares are held by insiders. Comparatively, 15.9% of Coherus BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Proteon Therapeutics and Coherus BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Proteon TherapeuticsN/AN/A-118.68%
Coherus BioSciences33.06%90.98%27.33%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Proteon Therapeutics and Coherus BioSciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Proteon Therapeutics0000N/A
Coherus BioSciences01502.83

Coherus BioSciences has a consensus price target of $27.8571, suggesting a potential upside of 82.73%. Given Coherus BioSciences' higher probable upside, analysts clearly believe Coherus BioSciences is more favorable than Proteon Therapeutics.

Summary

Coherus BioSciences beats Proteon Therapeutics on 10 of the 12 factors compared between the two stocks.

Mesoblast (NASDAQ:MESO) and Proteon Therapeutics (NASDAQ:PRTO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Insider & Institutional Ownership

2.8% of Mesoblast shares are held by institutional investors. Comparatively, 23.0% of Proteon Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 45.7% of Proteon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Mesoblast has a beta of 3.71, meaning that its share price is 271% more volatile than the S&P 500. Comparatively, Proteon Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Mesoblast and Proteon Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mesoblast13202.17
Proteon Therapeutics0000N/A

Mesoblast currently has a consensus price target of $14.55, indicating a potential upside of 58.50%. Given Mesoblast's higher possible upside, equities research analysts plainly believe Mesoblast is more favorable than Proteon Therapeutics.

Valuation & Earnings

This table compares Mesoblast and Proteon Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$32.16 million33.54$-77,940,000.00($0.74)-12.41
Proteon TherapeuticsN/AN/A$-20,730,000.00($1.15)-11.96

Proteon Therapeutics has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Proteon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mesoblast and Proteon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mesoblast-591.00%-18.69%-13.85%
Proteon TherapeuticsN/AN/A-118.68%

Summary

Mesoblast beats Proteon Therapeutics on 7 of the 12 factors compared between the two stocks.

Proteon Therapeutics (NASDAQ:PRTO) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Proteon Therapeutics and Cortexyme, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Proteon Therapeutics0000N/A
Cortexyme21402.29

Cortexyme has a consensus price target of $50.00, suggesting a potential upside of 37.48%. Given Cortexyme's higher possible upside, analysts clearly believe Cortexyme is more favorable than Proteon Therapeutics.

Profitability

This table compares Proteon Therapeutics and Cortexyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Proteon TherapeuticsN/AN/A-118.68%
CortexymeN/A-37.78%-35.24%

Earnings & Valuation

This table compares Proteon Therapeutics and Cortexyme's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteon TherapeuticsN/AN/A$-20,730,000.00($1.15)-11.96
CortexymeN/AN/A$-36,980,000.00($1.94)-18.75

Cortexyme is trading at a lower price-to-earnings ratio than Proteon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

23.0% of Proteon Therapeutics shares are held by institutional investors. Comparatively, 55.5% of Cortexyme shares are held by institutional investors. 45.7% of Proteon Therapeutics shares are held by insiders. Comparatively, 19.8% of Cortexyme shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Proteon Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Adverum Biotechnologies (NASDAQ:ADVM) and Proteon Therapeutics (NASDAQ:PRTO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

97.4% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 23.0% of Proteon Therapeutics shares are held by institutional investors. 12.4% of Adverum Biotechnologies shares are held by insiders. Comparatively, 45.7% of Proteon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Adverum Biotechnologies and Proteon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adverum BiotechnologiesN/A-32.23%-28.02%
Proteon TherapeuticsN/AN/A-118.68%

Valuation & Earnings

This table compares Adverum Biotechnologies and Proteon Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adverum Biotechnologies$250,000.004,287.38$-64,490,000.00($1.01)-10.85
Proteon TherapeuticsN/AN/A$-20,730,000.00($1.15)-11.96

Proteon Therapeutics has lower revenue, but higher earnings than Adverum Biotechnologies. Proteon Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Adverum Biotechnologies and Proteon Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adverum Biotechnologies02802.80
Proteon Therapeutics0000N/A

Adverum Biotechnologies presently has a consensus target price of $23.50, suggesting a potential upside of 114.42%. Given Adverum Biotechnologies' higher probable upside, analysts clearly believe Adverum Biotechnologies is more favorable than Proteon Therapeutics.

Risk and Volatility

Adverum Biotechnologies has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Comparatively, Proteon Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

Summary

Adverum Biotechnologies beats Proteon Therapeutics on 8 of the 11 factors compared between the two stocks.

Inhibrx (NASDAQ:INBX) and Proteon Therapeutics (NASDAQ:PRTO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Inhibrx and Proteon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InhibrxN/AN/AN/A
Proteon TherapeuticsN/AN/A-118.68%

Insider and Institutional Ownership

36.6% of Inhibrx shares are held by institutional investors. Comparatively, 23.0% of Proteon Therapeutics shares are held by institutional investors. 45.7% of Proteon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Inhibrx and Proteon Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InhibrxN/AN/AN/AN/AN/A
Proteon TherapeuticsN/AN/A$-20,730,000.00($1.15)-11.96

Analyst Ratings

This is a summary of recent ratings and target prices for Inhibrx and Proteon Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inhibrx00403.00
Proteon Therapeutics0000N/A

Inhibrx presently has a consensus price target of $34.6667, indicating a potential upside of 30.52%. Given Inhibrx's higher possible upside, research analysts clearly believe Inhibrx is more favorable than Proteon Therapeutics.

Summary

Inhibrx beats Proteon Therapeutics on 4 of the 5 factors compared between the two stocks.


Proteon Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
AVROBIO logo
AVRO
AVROBIO
1.7$10.54-4.6%$384.19 millionN/A-3.19
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$13.50-7.9%$349.93 millionN/A0.00High Trading Volume
Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.82-2.5%$347.25 millionN/A0.00Analyst Upgrade
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.18-10.1%$340.14 million$250,000.00-3.28Analyst Revision
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.30-2.1%$339.62 million$96.12 million-12.65Upcoming Earnings
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.71-6.2%$329.60 millionN/A-5.80High Trading Volume
Decrease in Short Interest
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.25-7.4%$329.00 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.20-3.4%$323.95 million$2.91 million-2.16Increase in Short Interest
News Coverage
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.81-11.0%$313.91 million$8.15 million-1.45Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.3$7.53-12.5%$306.30 million$15.36 million-11.41Upcoming Earnings
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.24-8.3%$300.60 millionN/A-3.80Upcoming Earnings
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$13.50-7.9%$290.94 millionN/A0.00
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.18-9.6%$270.20 million$4.13 million-4.84News Coverage
Cabaletta Bio logo
CABA
Cabaletta Bio
1.5$10.39-11.3%$249.93 millionN/A-7.58
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.